By AuntMinnie.com staff writers
February 26, 2019

iCAD plans to highlight its artificial intelligence (AI) software for digital breast tomosynthesis (DBT), ProFound AI, at the upcoming ECR 2019 in Vienna.

The software was cleared on 7 December 2018 by the U.S. Food and Drug Administration (FDA). It detects malignant soft-tissue densities and calcifications while offering radiologists scoring information that indicates the likelihood that a detection or case is malignant, the company said.

At the meeting, iCAD will also preview ProFound AI for 2D mammography, currently pending the CE Mark.

iCAD touts clinical results with Xoft Axxent brachytherapy
iCAD is highlighting positive clinical results for its Xoft Axxent electronic brachytherapy system that were presented at this week's American Society...
iCAD highlights study results of DBT software
Computer-aided detection (CAD) developer iCAD is touting the results of a new study using its digital breast tomosynthesis (DBT) cancer detection software....
iCAD touts study on radiation therapy savings
iCAD is touting a study that found intraoperative radiation therapy could directly save the U.S. healthcare system more than $630 million over the...
iCAD scores Chinese OK for balloon applicators
iCAD has received approval from the China Food and Drug Administration for the company's Xoft Axxent balloon applicators for the treatment of early-stage...
iCAD to highlight Xoft clinical results at AAPM
iCAD is directing attention to a presentation involving its Xoft Axxent electronic brachytherapy system at the upcoming American Association of Physicists...

Copyright © 2019 AuntMinnie.com

Last Updated np 2/25/2019 4:27:32 PM